Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026

SOLIGENIX, INC.

66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.
Blinded aggregate response rate in FLASH 2 remains higher than estimated rate used to design study, increasing confidence.
Investigator-initiated study: 75% of patients achieved treatment success, 3 complete responses with HyBryte at 18 weeks.
Cash ~$10.5M as of Sep 30, 2025, plus ~$500k from NJ NOL program; runway through 2026.
Positive Phase 2a results for SGX945 (Behçet’s) and SGX302 (psoriasis); Phase 2b design underway in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.